“…and a potential screening and predictive marker to immunotherapy [134] The wide spread of the mutations over variable codons [134] CBioportal, oncomine [132] RAS mutation analysis Excellent concordance with liver metastases in CRC patients who account for RAS mutations in exons 2 (codons 12 and 13), 3 (codons 59 and 61), and 4 (codons 117 and 146), predictive marker for monitoring the resistance to treatment with monoclonal antibodies (as monotherapy or combined with chemotherapy) [65] Not declared COSMIC, TCGA, GSEA, GO enrichment, KEGG, STRING, CPTAC, [125][126][127] OncoBEAMTM RAS One-step ultra-sensitive quantitative detection of plasmaderived KRAS and NRAS mutations for diagnosis, treatment, and immunotherapy monitoring of mCRC patients after surgery [84,95], significant low threshold detection [67], kinetical assaying of the mutated haploid GE quantity [67], prognostic value of MAF indicator in mCRC patients [67] Not declared MPprimer, Ultiplex [135,136] IdyllaTM RAS Accuracy sensitivity rate of ≤1% and ≤5 for KRAS mutations in exons 2, 3, and 4, respectively (potential assay for highly individualized anti-EGFR therapy and chemotherapy treatment decisions) [84] Two-step assay of RAS mutational status with lower clinical sensitivity than OncoBEAM assay [84] Biocartis Idylla™ System [84] SSCP method High sensitivity, specificity, for rapid diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) families based on hMLH1 and hMSH2 mutations with a good limit of detection (10%) [137][138][139][140] The longest turnaround time [137][138][139][140] GenBank, MUSCLE alignment program [141] Direct sequencing The gold standard, highly sensitive, and cost-effective, the quantitative measuring of an individual mutant allele in ctDNA for distinguishing CRC histological type [35,142,143] Limited potency for low amount mutant sequences detection in full wild-type DNA sequence context…”